Shares of Johnson & Johnson (NYSE:JNJ) have earned a consensus rating of “Hold” from the twenty-one research firms that are covering the stock, MarketBeat Ratings reports. Five investment analysts have rated the stock with a sell recommendation, eight have issued a hold recommendation and eight have issued a buy recommendation on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $133.79.

Several equities analysts have recently weighed in on JNJ shares. J P Morgan Chase & Co lifted their target price on shares of Johnson & Johnson from $140.00 to $148.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 16th. Vetr downgraded shares of Johnson & Johnson from a “hold” rating to a “sell” rating and set a $130.49 target price for the company. in a research note on Monday. Jefferies Group LLC set a $145.00 target price on shares of Johnson & Johnson and gave the stock a “hold” rating in a research note on Tuesday, August 15th. Wells Fargo & Company reiterated a “market perform” rating and issued a $135.00 target price (up previously from $132.00) on shares of Johnson & Johnson in a research note on Thursday, July 6th. Finally, BidaskClub downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Saturday, July 1st.

Shares of Johnson & Johnson (JNJ) traded down 0.27% on Friday, hitting $131.39. 4,334,862 shares of the company’s stock were exchanged. The stock’s 50 day moving average is $132.79 and its 200 day moving average is $129.43. The firm has a market cap of $352.65 billion, a P/E ratio of 22.23 and a beta of 0.79. Johnson & Johnson has a 12 month low of $109.32 and a 12 month high of $137.08. Johnson & Johnson also was the target of unusually large options trading activity on Wednesday. Investors bought 11,192 put options on the stock. This is an increase of approximately 244% compared to the typical daily volume of 3,249 put options.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Tuesday, July 18th. The company reported $1.83 EPS for the quarter, topping the consensus estimate of $1.79 by $0.04. The business had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The company’s revenue for the quarter was up 1.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.74 earnings per share. On average, equities analysts predict that Johnson & Johnson will post $7.18 earnings per share for the current year.

The business also recently announced a quarterly dividend, which was paid on Tuesday, September 12th. Shareholders of record on Tuesday, August 29th were given a dividend of $0.84 per share. The ex-dividend date of this dividend was Friday, August 25th. This represents a $3.36 annualized dividend and a yield of 2.56%. Johnson & Johnson’s payout ratio is presently 56.76%.

COPYRIGHT VIOLATION NOTICE: This article was published by Daily Political and is owned by of Daily Political. If you are reading this article on another website, it was stolen and reposted in violation of international trademark and copyright laws. The correct version of this article can be accessed at https://www.dailypolitical.com/2017/09/22/johnson-johnson-jnj-given-consensus-recommendation-of-hold-by-analysts.html.

In other Johnson & Johnson news, VP Paulus Stoffels sold 102,692 shares of Johnson & Johnson stock in a transaction that occurred on Monday, July 24th. The shares were sold at an average price of $133.14, for a total transaction of $13,672,412.88. Following the completion of the sale, the vice president now directly owns 230,342 shares in the company, valued at $30,667,733.88. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Dominic J. Caruso sold 82,591 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, July 20th. The shares were sold at an average price of $136.72, for a total transaction of $11,291,841.52. Following the sale, the vice president now owns 226,693 shares of the company’s stock, valued at $30,993,466.96. The disclosure for this sale can be found here. Insiders own 0.19% of the company’s stock.

A number of institutional investors have recently made changes to their positions in JNJ. Harding Loevner LP bought a new stake in Johnson & Johnson during the second quarter valued at approximately $106,000. Lenox Wealth Advisors Inc. lifted its position in Johnson & Johnson by 0.7% during the first quarter. Lenox Wealth Advisors Inc. now owns 871 shares of the company’s stock valued at $108,000 after purchasing an additional 6 shares during the last quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. lifted its position in Johnson & Johnson by 29.9% during the second quarter. Mitsubishi UFJ Securities Holdings Co. Ltd. now owns 870 shares of the company’s stock valued at $115,000 after purchasing an additional 200 shares during the last quarter. IHT Wealth Management LLC lifted its position in Johnson & Johnson by 46.4% during the second quarter. IHT Wealth Management LLC now owns 10,942 shares of the company’s stock valued at $122,000 after purchasing an additional 3,467 shares during the last quarter. Finally, Mountain Capital Investment Advisors Inc bought a new stake in Johnson & Johnson during the second quarter valued at approximately $124,000. Institutional investors and hedge funds own 65.90% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Analyst Recommendations for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.